Recent studies suggest the existence of cancer stem cells (CSC) and cancer progenitor cells (CPC), although strict definitions of neither CSC nor CPC have been developed. We have produced evidence that the principal oncoprotein of Epstein-Barr virus (EBV), latent membrane protein 1 (LMP1), which is associated with human malignancies, especially nasopharyngeal carcinoma (NPC), promotes tumor cell invasion and metastasis, as well as the epithelial-mesenchymal transition (EMT). However, whether LMP1 is involved in the development of CSC/CPC is still unclear. This study investigates whether the expression of EBV-LMP1 is related to the development of CSC/CPC. Analysis of cancer stem cell markers reveals that LMP1 induces the CD44 high
Recent studies have proposed that solid tumors are organized as a hierarchy composed of a spectrum of phenotypically distinct cells at different stages of maturation (25, 26) . The concept that cancer stem cells (CSC) include primitive rare CSC and cancer progenitor cells (CPC) has been developed (25) . At the apex of the hierarchy are primitive rare CSC, which possess extended self-renewal capabilities that allow them to perpetuate themselves and develop into CPC. CPC have only limited self-renewal abilities and can, in turn, differentiate into various types of cancer cells. In vivo, the primitive rare CSC rarely divide, whereas CPC proliferate rapidly. CD44 high CD24 low cells from breast cancer tissues were found to be more tumorigenic in immunodeficient mice than CD44 low CD24 high cells, and the results of these observations were used to support the CSC hypothesis for solid tumors (1) . Immortalized human mammary epithelial cells undergoing an epithelial-mesenchymal transition (EMT) are CSC-like, as evidenced by their CD44 high CD24 low phenotype and their capacity for self-renewal and for forming mammospheres (20) . Thus, the conjunction of EMT and the CD44 high CD24 low phenotype appears to be important for the understanding of CSC-like characteristics, although CSC have been characterized in solid tumors by using a variety of stem cell markers (9, 10, 33) . Epstein-Barr virus (EBV) is a human herpesvirus that is associated with several malignancies, such as Burkitt lymphoma (BL), Hodgkin lymphoma (HL), gastric cancer, and, most importantly, nasopharyngeal carcinoma (NPC) (24) . In all these tumors, EBV infection is predominantly latent. In latent infection, expressed EBV genes are restricted to six EBV nuclear antigens (EBNA1, -2, -3A, -3B, -3C, and -LP), three latent membrane proteins (LMP1, -2A, -and 2B), and two small nonpolyadenylated RNAs (EBER1 and -2). On the basis of the patterns of expression of these genes, latency is classified into three types. In type I latency, exemplified by BL, only EBNA1 and EBERs are expressed. In type II latency, exemplified by HL and NPC, EBNA1, EBERs, and the three LMPs are expressed. In type III latency, the full set of EBNAs and LMPs as well as EBERs are expressed, as in EBV B-cell lymphoproliferative diseases (24) .
LMP1, a member of the tumor necrosis factor receptor superfamily, is considered to be a potent oncogenic protein because of its transforming effects on rodent fibroblasts and because it is essential for the immortalization of B lymphocytes and epithelial cells (8, 30) . We have shown that LMP1 induces the expression of an array of cellular invasion and metastasis factors (15, 29, 34) . In particular, LMP1 can induce EMT via Twist or Snail (11, 12) , which coincides with the acquisition of CSC properties (20) . Several LMP1 variants, which originate from different types of EBV isolates and diseases, have been reported (14, 19, 22) . Among these variants, CAO-LMP1 was originally isolated from a patient with NPC and has been reported to be more tumorigenic than other variants (8, 21, 22) .
The aim of this study is to investigate whether the expression of an EBV-associated oncoprotein, LMP1, contributes to the development of CSC/CPC, by analyses with CAO-LMP1 which is associated with NPC. We also examine whether LMP1 affects tumorigenicity, cell proliferation, and the expression of CSC/CPC markers, including an EMT phenotype and stem cell-like genes, in epithelial cells. Finally, we propose here the new concept that LMP1 contributes to the generation of CPClike but not CSC-like cells.
MATERIALS AND METHODS
Cell cultures. KR4, KH1, KH2, HeLa, C666-1, and AdAH cells have been described previously (4, 7, 29) . C666-1, MDA-MB-231, and KR4 cells were maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS), penicillin, and streptomycin. The other cells were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% FBS, penicillin, and streptomycin.
Tumor sphere assay. For the tumor sphere assay, cells were seeded at a density of 1 ϫ 10 3 /ml in uncoated plastic dishes with a serum-free expansion medium (Stemcell Technologies, Vancouver, Canada) with epidermal growth factor and basic fibroblast growth factor (10 ng/ml each; PeproTech, Rocky Hill, NJ). Cells were cultured for 14 days, until sphere formation was observed. The number of sphere formations was analyzed with a t test. A P value under 0.05 was considered to be significant.
Plasmids and retroviral infection. The LMP1 expression vectors pSG5-CAO-LMP1 and pMRX-CAO-LMP1-IRES-GFP have been described previously (14, 23) . From these plasmids, cDNA of the CAO-LMP1 fragment digested by EcoRI and NotI was introduced into the same site of the pFB-Neo vector (Stratagene, Santa Clara, CA), and the resultant plasmid was named pFB-LMP1 (CAO-LMP1). Retroviruses were produced as described previously (23) . AdAH cells were infected with these viruses in the presence of Polybrene. Stable cell lines were established by cultivating AdAH cells in the presence of G418 (Invitrogen, Carlsbad, CA). After culturing for 7 days with G418, we selected single clones using cloning paper (Sigma-Aldrich, St. Louis, MO).
siRNA transfection. LMP1 and negative-control small interfering RNAs (siRNA) were chemically synthesized by Hokkaido System Sciences (Sapporo, Hokkaido, Japan). The sequences of LMP1 siRNA and negative-control siRNA have been described elsewhere (3). The EBV-positive NPC cell line C666-1 was seeded into 60-mm-diameter dishes at 6 ϫ 10 5 cells per dish on the day before transfection. Lipofectamine 2000 (Invitrogen) was used for transfection, with a final siRNA concentration at 100 nM for 72 h, for subsequent experiments.
RT-PCR analysis. Total RNA was extracted using an RNeasy Plus Mini kit (Qiagen, Hilden, Germany) and was reverse transcribed with SuperScript III (Invitrogen). The resulting cDNAs were used for amplification of LMP1 and ␤-actin cDNA by the use of Taq DNA polymerase (Takara Bio, Ootu, Japan) as described previously (22) . For SYBR green real-time reverse transcriptase PCR (RT-PCR), reactions were performed in triplicate using QuantiFast SYBR green PCR (Qiagen) on a LightCycler system (Roche, Mannheim, Germany). All primers were made using the QuantiTect primer assay (Qiagen). All quantitations were normalized to an endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative quantitative value for each target gene compared with the calibrator for that target is expressed as 2 Ϫ ͑C T Ϫ C C ͒(C T and C C are the mean threshold cycle differences for the target and control, respectively, after normalization to GAPDH). The relative expression levels of samples are presented by a semilog plot.
Flow cytometry and cell sorting. Cells were labeled with the following antihuman antibodies: phycoerythrin (PE)-conjugated anti-CD24, anti-CD29, and anti-CD49b, fluorescein isothiocyanate (FITC)-conjugated anti-CD49f, allophycocyanin (APC)-conjugated anti-CD44 and anti-CD90, PE-conjugated anti-CD117, APC-conjugated anti-CXCR4 (BD Pharmingen, San Diego, CA), FITC-conjugated anti-EpCAM (Abcam, Cambridge, MA), and PE-conjugated anti-ABCG2, anti-CD166 (R & D Systems, Minneapolis, MN), and anti-CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany). Labeled cells were detected using a JSAN cell sorter (Bay Bioscience, Kobe, Japan). Appropriate isotypes of nonrelated antibodies were used as controls. For cell sorting, a cocktail of PE-conjugated anti-CD24 and APC-conjugated anti-CD44 was used. MDA-MB-231 or MCF-7 cells were used for positive staining of CD44 or CD24, respectively (28) . Labeled cells were analyzed and sorted using JSAN. For the positive population, only the 5% of most brightly stained cells were selected. For side population (SP) analysis, cells (1 ϫ 10 6 /ml) were incubated in prewarmed Hanks' balanced salt solution with 2% fetal bovine serum, 10 mM HEPES buffer, and 1% penicillin-streptomycin, containing freshly added Hoechst 33342 (final concentration, 5 g/ml), for 90 min or 120 min at 37°C with intermittent mixing. Cells were incubated with the Hoechst dye with or without verapamil (300 M). At the end of incubation, cells were spun down and resuspended in ice-cold buffer. Propidium iodide (PI) (1 mg/ml) was added before flow cytometric analysis.
Immunoblotting. Immunoblotting was carried out as described previously (29) . Antibodies against the following proteins were used: LMP1 (Dako, Glostrup, Denmark), KLF4 (H-180), Oct4 (C-10), E-cadherin (G-10), cytokeratin 14 (CK14), and ␣-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA), nestin (10C2; Novus Biologicals, Littleton, CO), c-myc (9E10; BioLegend, San Diego, CA), fibronectin (IST-4; Sigma-Aldrich), Nanog (1E6C4; Cell Signaling, Danvers, MA), vimentin (V9), CD24 (SN3), and CK18 (Thermo Scientific, Cheshire, United Kingdom), ABCG2 (BCRP1) and CD44 (EPR1013Y) (Millipore, Temecula, CA), CK19 (Abcam), and N-cadherin (BD Bioscience Pharmingen).
Cell proliferation assay. A total of 1.5 ϫ 10 3 cells were seeded into a 96-well plate, and cell proliferation was performed using a CellTiter 96 Aqueous One solution cell proliferation kit (Promega, Madison, WI) as described previously (35) . Four samples for each group were used for analysis. Similarly, the cell proliferation rate was determined with a CellTrace CFSE (carboxyfluorescein succinimidyl ester) cell proliferation kit (Invitrogen). Cells (5 ϫ 10 6 /ml) were harvested, washed twice in phosphate-buffered saline (PBS), and then stained with 20 M CFSE for 15 min at 37°C. Residual CFSE was removed by washing twice with PBS, and cells were seeded in 6-well plates and were grown in DMEM with 1% fetal bovine serum. CFSE fluorescence intensity was measured by fluorescence-activated cell sorter (FACS) analysis every 48 h for 4 days.
Soft-agar colony formation assay. A soft-agar assay was performed by seeding cells in a layer of 0.35% agar-DMEM-FBS over a layer of 0.5% agar-DMEM-FBS. Cultures were maintained at 37°C. On day 21 after seeding, cells were fixed with pure ethanol containing 0.05% crystal violet, and the colony-forming efficiency was quantified by light microscopy.
Injection of cells into immunodeficient mice. AdAH-pFB-Neo or AdAH-pFB-LMP1 cells in a volume of 0.1 ml of PBS were inoculated subcutaneously into female BALB/c-nu/nu or NOD/SCID mice aged 6 weeks (Charles River Japan, Yokohama, Japan). The research plan was approved by the Ethics Committee of the Laboratory for Animal Experiments, School of Medicine, Kanazawa University. All the mice were sacrificed at 12 weeks after injection.
Fluorescence immunostaining. Fluorescent immunostaining was performed as described previously (35) . Antibodies against LMP1, Twist, Snail, E-cadherin, vimentin, fibronectin, N-cadherin, CK14 (Santa Cruz Biotechnology), CK18 (Thermo Scientific), and CK19 (Abcam) were used for staining.
RESULTS

LMP1-expressing cells exhibit a CD44
high CD24 low phenotype that enhances self-renewal properties. There are several reports that only cells with the CD44 high CD24 low phenotype exhibit CSC/CPC properties (1, 20) . We first investigated hybrid somatic cell lines generated from EBV-negative epithelial cells (HeLa) and EBV-positive type III lymphoblastoid cells (KR4) (7) . The fusion cell lines KH1 and KH2 exhibit type II EBV latency, as do NPC cells. As shown in Fig. 1A LMP1 induces morphological change and a CD44 high CD24 low profile as well as the self-renewal property in nasopharyngeal epithelial cells. To further assess whether LMP1 expression actually enhances CSC/CPC properties, human epithelial cell lines stably expressing LMP1 were tested. In this study, we focused on an LMP1 variant, CAO-LMP1, as a representative form of LMP1, since CAO-LMP1 has been detected most frequently in NPC worldwide and has been reported to be more tumorigenic than other variants (8, 23) .
To establish stable epithelial cell lines that express LMP1, AdAH cells (an EBV-negative nasopharyngeal epithelial cell line) were infected either with a retrovirus vector carrying LMP1 or with an empty retrovirus vector, followed by selection in neomycin. Finally, a representative clone with the strongest Fig. 2A) . The LMP1-expressing clone tends to grow in a scattered pattern, in contrast to the cobblestone-like pattern of the LMP1-negative clone and parental AdAH cells. To further clarify whether LMP1 signaling affects the CD44/ CD24 expression profiles of these cells, flow cytometric and Western blot analyses of AdAH-pFB-Neo and AdAH-pFB-LMP1 cells were performed on the basis of CD44 and CD24 expression. The distributions of the cell surface markers CD44 and CD24 in the newly established cell lines with or without LMP1 are shown in Fig. 2B and C. AdAH-pFB-LMP1 expressed high CD44 but low CD24 levels compared with those of the AdAH-pFB-Neo control.
Finally, we tested whether LMP1 expression in nasopharyngeal epithelial cells enhanced self-renewal properties. We examined tumor sphere formation with AdAH-pFB-Neo and AdAH-pFB-LMP1 cells. AdAH-pFB-Neo and AdAHpFB-LMP1 cells were cultured in suspension with serumfree medium to generate tumor spheres. As shown in Fig.  2D , AdAH-pFB-LMP1 cells formed more than twice as many tumor spheres as the control (P Ͻ 0.05). These data show that LMP1 expression in epithelial cells induces this self-renewal property.
LMP1 promotes rapid cell growth and high tumorigenicity. To examine the cellular effects of LMP1, the growth kinetics of AdAH cells expressing LMP1 were examined over 7 days (Fig.  3A) . The growth of AdAH-pFB-LMP1 cells was more rapid than that of AdAH-pFB-Neo cells (Fig. 3A) . This result is compatible with previous reports that LMP1 causes rapid cellular growth (8, 23) .
To assess the proliferation rate at the single-cell level, AdAH-pFB-Neo and AdAH-pFB-LMP1 cells were stained with CFSE; this stain is evenly distributed in the cytoplasm and is stoichiometrically distributed to the daughter cells during cell division. The intensity of CFSE was clearly lower in AdAH-pFB-LMP1 cells than in AdAH-pFB-Neo cells (Fig. 3B) . This result supports findings that LMP1 induces rapid cellular proliferation.
Anchorage-independent cell growth is frequently used as an assay for tumorigenicity in CSC/CPC studies (16) . Tumorigenic cells can form more colonies in semisolid soft-agar medium than less tumorigenic cells. Using this assay, we investigated whether LMP1 affects colony formation in such a medium. AdAH-pFB-Neo or AdAH-pFB-LMP1 cells were plated onto a semisolid agar medium. Cells were analyzed by light microscopy 21 days posttransduction. LMP1-expressing AdAH cells generated more and larger colonies in soft agar than LMP1-negative cells (Fig. 3C) .
Finally, the effect of LMP1 on tumorigenicity was assessed by inoculating AdAH cells into BALB/c-nu/nu mice. immunodeficiency than BALB/c-nu/nu mice, were inoculated with AdAH-pFB-LMP1 or AdAH-pFB-Neo cells. With large numbers of cells (1 ϫ 10 7 ), palpable tumors developed in almost all cases (Table 2) . However, when lower numbers of cells (1 ϫ 10 6 to 1 ϫ 10 4 ) were inoculated, only the LMP1-expressing AdAH clone formed tumors (Table 2 ). These results indicate that LMP1 enhances the tumorigenicity of human epithelial cells in culture.
We conclude that LMP1 has substantial ability to induce CSC/CPC properties in human epithelial cells.
LMP1 silencing reduces CD44 high CD24 low properties, accompanied by lowering of the cellular proliferation rate in naturally derived EBV-positive NPC cell lines. To further verify that LMP1 could affect CD44 high CD24 low properties with rapid cellular proliferation in physiological NPC cell lines, we made LMP1-silencing systems by chemical synthesis of siRNA in C666-1 cells. C666-1 is a naturally occurring carcinoma cell line derived from an NPC biopsy specimen, and EBV genes, including LMP1, are expressed (4). First, we detected LMP1 transcriptional expression to identify the LMP1 siRNA that produced the desired reduction of LMP1 expression. As shown in Fig. 4A , LMP1 siRNA could reduce LMP1 expression in C666-1 cells, whereas control siRNA did not. In subsequent flow cytometric analysis, C666-1 cells with control siRNA ex- (Fig. 4C) . These results suggest that LMP1 silencing reduces CD44 high CD24 low properties and is accompanied by repression of rapid cellular proliferation in this naturally occurring NPC cell line.
LMP1 induces EMT. Because EMT produces cells expressing the stem cell phenotype (20) , it is of particular interest to test whether the LMP1-induced CSC/CPC show EMT characteristics. Representative EMT markers were thus analyzed by real-time RT-PCR. As shown in Fig. 5A , LMP1 induced higher levels of Twist and Snail mRNAs. Furthermore, as shown in Fig. 5B and C, the AdAH-pFB-LMP1 cell line expressed higher levels of the Twist and Snail proteins than the control cell line. Since Twist and Snail are known inducers of the EMT, we determined expression of EMT markers in the newly established cell lines at both the mRNA and protein levels.
LMP1 downregulated the level of an epithelial cell marker, E-cadherin (Fig. 5A, B, and D) . In contrast, expression of the mesenchymal markers fibronectin, vimentin, and N-cadherin was induced in response to LMP1 expression (Fig. 5A, B, and  D) . Taken together, these results indicate that induction of CSC/CPC by LMP1 is accompanied by upregulation of EMT markers.
LMP1 expression upregulates other cell surface cancer stem cell markers. Since LMP1 induces the CD44 high CD24 low phenotype, which results in self-renewal ability and EMT-like cellular changes, we investigated whether LMP1 induces other markers of CSC/CPC. To examine the profile of CSC/CPC markers in LMP1-expressing cells, the expression of a panel of known stem cell markers, such as CD29, CD49b, CD49f, CD90, CD117, CD133, CD166, ABCG2, EpCAM, and CXCR4, was determined using flow cytometric analysis of nasopharyngeal epithelial cells with or without LMP1 expression (27) . CD133, ABCG2, and EpCAM were expressed in LMP1-expressing cells (Fig. 6A) . The expression of integrins that are CSC/CPC markers, such as CD29 (␤1 integrin), CD49b (␣2 integrin), and CD49f (␣6 integrin), was also upregulated by LMP1 expression (Fig. 6A) . However, LMP1 did not affect the expression of CD90, CD117, CD166, or CXCR4 (data not shown). These results suggest that LMP1 has heterogeneous effects on the expression of cell surface stem cell markers other than CD44 and CD24.
LMP1-induced cytokeratin profiles are consistent with an undifferentiated cell state. Cytokeratins (CKs) are indispensable markers for the classification of a cell's differentiation status. CK18 is expressed in differentiated cells, whereas CK14 is a basal cell keratin. CK19 is an undifferentiated keratin and is known as a normal stem cell marker (5) . To further investigate the differentiation of LMP1-expressing cells, CK14, -18, and -19 were analyzed by immunofluorescence. As shown in Fig. 6B , LMP1 expression increased the levels of CK14 and -19, whereas CK18 was downregulated upon LMP1 expression (Fig. 6B) . Immunoblot analysis revealed that LMP1 leads to increases in the levels of CK14 and CK19 and a decrease in that of CK18 (Fig. 6C) . These findings suggest that LMP1 affects the CK profiles, shifting them toward an undifferentiated status.
Expression profiles of CPC-associated genes in LMP1-expressing cells. It has been reported that ABCG2 ϩ cells are CPC and have rapid cell cycling, whereas ABCG2
Ϫ cells are CSC and display little or slow cell cycling (25, 35) . Previous reports showed that the expression of certain stem cell-like genes, such as Oct4, was decreased in ABCG2 ϩ cells (25, 26) . Similarly, repression of pluripotent stem cell-like genes, such as Oct4 and Nanog, is specific in CPC, whereas induction of such pluripotent stem cell-like genes is specific for the CSC phenotype in certain carcinoma cells (13, 32) . For convenience, we defined the repression of several pluripotent stem cell-like genes or the induction of ABCG2 as CPC associated in this study.
According to the finding, as shown in Fig. 7A and B, that LMP1 induces ABCG2, we propose here that LMP1-expressing cells can be classified as having a CPC-like phenotype. To further analyze the characteristics of LMP1-expressing cells, levels of representative CPC-associated markers in AdAH cells with or without LMP1 expression were determined by realtime RT-PCR and immunoblotting ( Fig. 7A and B) . As expected, LMP1 downregulated levels of Nanog, nestin, and Oct4 compared with levels in the vector control. However, LMP1-expressing cells exhibited higher levels of KLF4 and c-Myc than the vector control.
A recent study showed that another EBV gene product, LMP2A, induces EMT as well as stem-like cancer cells by increasing side population (SP) cells, which can cause efflux of the DNA binding dye Hoechst 33342 from the cell membrane (9, 10, 16) . SP cells may indicate primitive CSC, because SP cells normally exist in the quiescent phase, as do stem cells, and have stem cell characteristics (9, 10, 31, 36) . To determine whether LMP1-expressing cells exhibit increased numbers of SP cells, we examined AdAH-pFB-LMP1 and AdAH-pFBNeo cells. However, as shown in Fig. 7C, LMP1 does not affect the number of SP cells at different times of incubation (0.19% in AdAHpFB-Neo versus 0.2% in ADAH-PFB-LMP1 cells at 90 min; 0.33% in AdAH-PFB-Neo versus 0.42% in AdAHpFB-LMP1 cells at 120 min). LMP1 does not increase the number of SP cells over that in AdAH-pFB-Neo cells. These results suggest that the CPC phenotype inducible by LMP1 has heterogeneous expression of CPC-associated markers.
DISCUSSION
It has been reported that tumorigenic potential is exhibited almost exclusively by cells within the CD44 ϩ population (1). Thus, the identification of CD44 is the first step toward unambiguous characterization of cancer stem cells. However, whether a low level of CD24, such as that shown in our study, is essential for the phenotype of cancer stem cells is controversial. Al-Hajj et al. showed that a population of CD44 high CD24 low cells was highly tumorigenic (1). In contrast, Li et al. identified a highly tumorigenic subpopulation of CD44 high CD24
high pancreatic cancer cells (17) . These discrepancies may be attributable to differences in cancer cell types, though our results are similar to those of Al-Hajj et al. (1) . Thus, CD24 status is not essential for the identification of CSC/CPC.
Recent studies have proposed that solid tumors are organized as a hierarchy composed of a spectrum of CSC, CPC, and differentiated cancer cells (25, 26) . According to these studies, certain markers, such as ABCG2 and integrin ␣2␤1, are putative markers that distinguish CSC from CPC (25, 26) . Similarly, there are several reports that CD133 and integrin ␣2␤1 are enriched in CPC (6, 25) . From these studies and the present study, we propose here that LMP1 is a potential inducer of the phenotype of CPC but not CSC (Table 3) . CSC have greater self-renewal abilities and proliferative potentials but normally have slow cycling. In contrast, CPC proliferate more actively and exhibit rapid cycling but a lower self-renewal capacity. However, the question remains: if LMP1 can initiate CPC, what factors produce primitive CSC? A recent report from Kong et al. (16) showed that LMP2A induces EMT as well as stem-like cancer cells by increasing the number of SP cells, suggestive of primitive CSC, because SP cells normally exist in the quiescent phase, as do stem cells (9, 10, 31, 36) . Burkert et al. proposed that the concept of the SP phenotype as a universal marker of stem cells does not apply to certain cancer cells (2) . Whether the SP phenotype is a CSC marker is still controversial. In the present study, LMP1 did not affect the number of SP cells. Thus, we hypothesize here that LMP2A is a true inducer of primitive CSC, whereas LMP1 induces CPC. Both LMP1 and LMP2A induce CSC or CPC phenotypes; however, to clarify the differences between these two EBV products, further investigations are required.
In the present study, expression of some CPC-associated genes, such as Oct4 and Nanog, was decreased with LMP1 expression. Since repression of certain pluripotent stem celllike genes is a feature of CPC, these results support the hypothesis that LMP1 induces the CPC but not the CSC phenotype (25, 26) . However, with LMP1 induction, other "stemness" genes, such as the c-Myc and KLF4 genes, are upregulated. These genes are closely related to oncogenic activity or malignant potential (18, 33) . These results suggest that the LMP1-inducible CPC phenotype has heterogeneous effects on the expression of CPC-associated genes. Further investigations are required for the definition of CSC/CPC phenotypes.
During the process of cancer metastasis, which is enabled by EMT, the disseminated cancer cells seem to acquire self-renewal abilities, similar to those exhibited by stem cells. The present and previous studies have shown that LMP1 induces EMT via Twist and Snail (11, 12) . In this study, we show that LMP1-induced human epithelial cells have both CSC/CPC and EMT characteristics, confirming the close link between CSC/ CPC and an EMT mechanism in LMP1-expressing cells. Keratin profiles in LMP1-expressing cell lines were also investigated. Here we show that LMP1 affects the CK profile, shifting it toward an undifferentiated status (5). Our results suggest that LMP1 is essential for maintaining the undifferentiated status in EBV-associated malignancies, such as NPC. These results suggest that LMP1 signaling is a key regulator of the pathobiological characteristics of NPC, not only its highly metastatic properties but also its undifferentiated status.
In conclusion, LMP1 is the first identified initiator that induces CPC but not CSC. Understanding the role of EBV infection in the generation of CSC/CPC in NPC can be an important step toward further clarification of the biological significance of general CSC and CPC theories.
